Aflatoxins as a cause of hepatocellular carcinoma

Journal of Gastrointestinal and Liver Diseases

Volumn 22, Issue 3, 2013, Pages 305-310

  Kew, Michael C ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Aflatoxins; Contaminant; Eastern Asia; Hepatocellular carcinoma; South America; Staple foods; Sub Saharan Africa

Indexed keywords

AFLATOXIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; MYCOTOXIN; CARCINOGEN;

ASPERGILLUS FLAVUS; ASPERGILLUS PARASITICUS; CANCER MORTALITY; CELL CYCLE REGULATION; ENVIRONMENTAL EXPOSURE; FOOD CONTAMINATION; GENE MUTATION; HEALTH HAZARD; HEPATITIS B; HUMAN; HYPERPLASIA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; NONHUMAN; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE; ANIMAL; CATERING SERVICE; CELL TRANSFORMATION; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECTS; FOOD CONTROL; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; METABOLISM; RISK ASSESSMENT; TOXICITY;

AFLATOXINS; ANIMALS; ASPERGILLUS FLAVUS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; FOOD MICROBIOLOGY; FOOD SUPPLY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84884597715     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. IARC. Monographs on the evaluation of carcinogenic risks in humans. International Agency for Research on Cancer (IARC). IARC Press, Lyon, France 2002, Vol. 82.
2. Williams JH, Phillips TD, Jolly PE, Stiles JK, Jolly CM, Aggarwal D. Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. Am J Clin Nutr 2004; 80: 1106-1122.
3. Strosnider H, Azziz-Baumgartner E, Banziger M, et al. Work group report: Public health strategies for reducing aflatoxin exposure in developing countries. Environ Health Perspect 2006; 114: 1898-1903.
4. Liu Y, Chang CC, Marsh GM, Wu F. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer 2012; 48: 2125-2136.
5. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010; 118: 818-824.
6. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000; 46: 381-393.
7. Wild CP, Shrestha SM, Anwar WA, Montesano R. Field studies of aflatoxin exposure, metabolism and induction of genetic alterations in relation to hepatitis B virus infection and hepatocellular carcinoma in the Gambia and Thailand. Toxicol Lett 1992; 64-65 Spec No: 455-461.
8. Wild CP, Pionneau FA, Montesano R, Mutiro CF, Chetsanga CJ. Aflatoxin detected in human breast milk by radioimmunoassay. Int J Cancer 1987; 40; 328-333.
9. Leong YH, Rosma MA, Latiff AA, Izzah AN. Association of serum aflatoxin B1-lysine adductlevel with socio-demographic factors and aflatoxin intake from nuts and related nut products in Malaysia. Int J Hyg Environ Health 2012; 215: 368-372.
10. Bennet JW, Klich M. Mycotoxins. Clin Micriobiol Rev 2003; 16: 497-516.
11. Fink-Gremmels J. Mycotoxins: their implications for human and animal health. Vet Q 1999; 21: 115-120.
12. Wogan GN, Kensler TW, Groopman JD. Present and future directions of translational research on aflatoxins and hepatocellular carcinoma. A review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2012; 29: 249-257.
13. Brown RL, Chen ZY, Cleveland TE, Russin JS. Advances in the development of host resistance in corn to aflatoxin contamination by Aspergillus flavus. Phytopathology 1999; 89: 113-117.
14. Wild CP, Hasegawa R, Barraud L, et al. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans. Cancer Epidemiol Biomarkers Prev 1996; 5: 179-189.
15. Wogan GN. Aflatoxin exposure as a risk factor in the etiology of hepatocellular carcinoma. In: Okuda K, Tabor E (eds). Liver Cancer. Churchill Livingstone, New York 1997: S1-S8.
16. Wild CP, Turner PC. The toxicity of aflatoxins as a basis for public health decisions. Mutagenesis 2002; 17: 471-481.
17. Sudakin DL. Dietary aflatoxin exposure and chemoprevention of cancer: a clinical review. J Toxicol Clin Toxicol 2003; 41: 195-204.
18. Kensler TW, Qian GS, Chen JG, Groopman JD. Translational strategies for cancer prevention in liver. Nat Rev Cancer 2003; 3: 321-329.
19. McLean, Dutton MF. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol Ther 1995; 65: 163-192.
20. IARC. Some traditional herbal medicines, some mycotoxins, Naphthalene and Styrene. IARC Press, Lyon 2002.
21. Kamdem LK, Meineke I, Godtel-Armbrust U, Brockmöller J, Wojnowski L. Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1. Chem Res Toxicol 2006; 19: 577-586.
22. Bressac B, Kew MC, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-431.
23. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428.
24. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007; 26: 2166-2176
25. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
26. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
27. McLean M, Dutton MF. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol Ther 1995; 65: 163-192.
28. Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, et al. Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. PLoS One 2012; 7: e737707.
29. Kirk GD, Camus-Randon AM, Mendy M, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia. J Natl Cancer Inst 2000; 92: 148-153.
30. Gouas D, Shi H, Hainaut P. The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy. Cancer Lett 2009; 286: 29-37.
31. Kirk GD, Lesi OA, Mendy M, et al. 249(Ser) TP53 mutation in plasma DNA, hepatitis B virus infection, and risk of hepatocellular carcinoma. Oncogene 2005; 24: 5858-5867.
32. Sell S, Hunt JM, Dunsford HJ, Chisari FV. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res 1991; 51: 1278-1285.
33. Bannasch P, Khoshkhou NI, Havker HJ, et al. Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res 1995; 55: 3318-3330.
34. Cova L, Wild CP, Mehrotra R, et al. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks. Cancer Res 1990; 50: 2156-2163.
35. Li Y, Su JJ, Qin LL, Yang C, Ban KC, Yan RQ. Synergistic effect of hepatitis B virus and aflatoxin B1 in hepatocarcinogenesis in tree shrews. Ann Acad Med Singapore 1999; 28: 67-71.
36. Yeh FS, Mo CC, Yen RC. Risk factors for hepatocellular carcinoma in Guangxi, People's Republic of China. Nat Cancer Inst Monogr 1985; 69: 47-48.
37. Groopman JD, Wang JS, Scholl P. Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. Can J Physiol Pharmacol 1996; 74: 203-209.
38. Kew MC. Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Internat 2003; 23: 405-409.
39. Kuang SY, Lekawanavijit S, Maneekarn N, et al. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinoma from Thailand. Cancer Epidemiol Biomarkers Prev 2005; 14: 380-384.
40. Kirk GD, Bah E, Montesano R. Molecular epidemiology of human liver cancer: insights into etiology, pathogenesis and prevention from the Gambia, West Africa. Carcinogenesis 2006; 27: 2070-2082.
41. Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett 2009; 286: 22-28.
42. Wogan GM. Aflatoxin exposure as a risk factor in the etiology of hepatocellular carcinoma. In: Okuda K, Tabor E (eds). Liver Cancer. Churchill, Livingstone, New York 1997: S1-S8.
43. Ross RK, Yuan JM, Yu MC, et al. Urinary aflatoxin biomarkers and the risk of hepatocellular carcinoma. Lancet 1992; 339: 943-946.
44. Qian GS, Ross RK, Yu MC, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1994; 3: 3-10.
45. Wang JS, Qian GS, Zarba A, et al. Temporal patterns of aflatoxinalbumin adducts in hepatitis B surface antigen-positive and antigennegative residents of Darxin, Qidong County, People's Republic of China. Cancer Epidemiol Biomarkers Prev 1996; 5: 253-261.
46. Lunn RM, Zhang YJ, Wang LY, et al. p53 mutations, chronic hepatitis B infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57: 3471-3477.
47. Omer RE, Kuijsten A, Kaduru AM, et al. Population-attributable risk of dietary aflatoxins and hepatitis B virus infection with respect to hepatocellular carcinoma. Nutr Cancer 2004; 48: 15-21.
48. Sun Z, Lu P. Gail MH, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 1999; 30; 379-383.
49. Chen CJ, Zhang YJ, Lu SN, Santella RM. Aflatoxin B1 adducts in smeared tumor tissue from patients with hepatocellular carcinoma. Hepatology 1992; 16: 1150-1155.
50. Allen SJ, Wild CP, Wheeler JG, et al. Aflatoxin exposure, malaria and hepatitis B infection in rural Gambian children. Trans R Soc Trop Med Hyg 1992; 86: 426-430.
51. Turner PC, Mendy M, Whittle H, Fortuin M, Hall AJ, Wild CP. Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop Med Int Health 2000; 5: 837-841.
52. Wang LY, Hatch M, Chen CJ, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996; 67: 620-625.
53. Ozturk M. Bressac B, Pusieux A, et al. A p53 mutational hotspot in primary liver cancer is geographically localised in high aflatoxin areas of the world. Lancet 1991; 338; 260-265.
54. Coursaget P, Depril N, Chabaud M, et al. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinoma from Senegal. Br J Cancer 1993; 67: 1395-1397.
55. Stern M, Umbach DM, Yu MC, London SJ, Zhang ZQ, Taylor JA. Hepatitis B, aflatoxin B1, and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a metaanalysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001; 10: 617-625.
56. Kew MC. Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26: 144-152.
57. Ahn JY, Jung EY, Kwun HJ, Lee CW, Sung YC, Jang KL. Dual effects of hepatitis B virus x protein the regulation of cell cycle control depending on the status of cellular p53. J Gen Virol 2002; 83: 2765-2772.
58. Madden CR, Finegold MJ, Slagle BL. Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J Virol 2002; 76: 11770-11774.
59. Jia L, Wang XW, Harris CC. Hepatitis B virus x protein inhibits nucleotide excision repair. Int J Cancer 1999; 80: 875-879.
60. Chisari FV, Klopchin K, Moriyama T, et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B transgenic mice. Cell 1989; 59: 1145-1156.
61. Ohshima H, Bartsch H. Chronic infection and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994; 305: 253-264.
62. Hussain SP, Aquilar F, Amstad P, Cerutti P. Oxy-radical induced mutagenesis of hotspot codons 248 and 249 of the human p53 gene. Oncogene 1994; 9; 2277-2281.
63. Zhang YJ, Ahsan H, Chen Y, et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adducts in human hepatocellular carcinoma. Mol Carcinog 2002; 35: 85-92.